Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.

ABSTRACT:

Aim

To assess the effects of oral semaglutide on postprandial glucose and lipid metabolism, and gastric emptying, in subjects with type 2 diabetes (T2D).

Materials and methods

In this randomized, double-blind, single-centre, crossover trial, subjects with T2D received once-daily oral semaglutide (escalated to 14 mg) followed by placebo, or vice versa, over two consecutive 12-week periods. Glucose and lipid metabolism, and gastric emptying (paracetamol absorption) were assessed before and after two types of standardized meals (standard and/or fat-rich) at the end of each treatment period. The primary endpoint was area under the glucose 0-5-h curve (AUC_0-5h ) after the standard breakfast.

Results

Fifteen subjects were enrolled (mean age 58.2 years, HbA1c 6.9%

SUBMITTER: Dahl K 

PROVIDER: S-EPMC8251575 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature